News
AGMB
16.00
+2.89%
0.45
AgomAb Therapeutics Closes Nasdaq IPO of 12.5 Million ADSs
TipRanks · 2d ago
AGOMAB ANNOUNCES CLOSING OF INITIAL PUBLIC OFFERING
Reuters · 2d ago
Opening Day: SpyGlass Pharma soars in debut after strongly priced IPO
TipRanks · 2d ago
U.S. IPO Weekly Recap: 7 IPOs Make It One Of The Busiest Weeks In 4 Years
Seeking Alpha · 5d ago
SpyGlass Pharma surges on public debut; AgomAb falls
Seeking Alpha · 5d ago
BUZZ-U.S. STOCKS ON THE MOVE-SpyGlass, Agomab, Piper Sandler, Molina
Reuters · 5d ago
Agomab opens at $14.70, IPO priced at $16.00
TipRanks · 5d ago
AGOMAB THERAPEUTICS AMERICAN DEPOSITARY SHARES OPEN AT $14.70 IN NASDAQ DEBUT VS $16 IPO PRICE
Reuters · 5d ago
SpyGlass Agomab to make Nasdaq debuts with a combined $350M offering
Seeking Alpha · 5d ago
Agomab indicated to open at $15.50, IPO priced at $16
TipRanks · 5d ago
Agomab 12.5M share IPO priced at $16.00
TipRanks · 6d ago
U.S. IPO Weekly Recap: Trio Of Sizable Listings Underwhelm To Close Out January
Seeking Alpha · 01/31 03:25
More
Webull provides a variety of real-time AGMB stock news. You can receive the latest news about AgomAb Therapeutics NV through multiple platforms. This information may help you make smarter investment decisions.
About AGMB
Agomab Therapeutics NV is a Belgium-based biotech company. The Company is engaged in the development of antibodies for damaged tissues. It develops novel treatments that aim to preserve and restore organ function in fibrotic diseases. It also develops growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues. The Company targets growth factors and modulates related molecular pathways through monoclonal antibodies and small molecule compounds to resolve fibrosis, regenerate tissue and restore organ functionality. It works with academic institutions and industrial partners to develop treatment options for patients.